Bayforest Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Bayforest Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-385	Closed	-$72.8K	–	1011
2025 Q4	$72.8K	Buy	+385	New	+$74K	0.05%	530

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Bayforest Capital's LGND Position: Q1 2026 in Review

Bayforest Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 385 shares — an estimated $72.8K sold.

Bayforest Capital first reported a position in LGND in Q4 2025 and held it in 1 quarter. The position peaked at $72.8K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Bayforest Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bayforest Capital sold 385 Ligand Pharmaceuticals shares in Q1 2026, an estimated $72.8K.
Bayforest Capital first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Bayforest Capital's Ligand Pharmaceuticals position peaked at $72.8K in Q4 2025.
357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.